Vestibular rehabilitation was found to ameliorate headache, dizziness, and psychological factors in patients with vestibular migraine or a combination of tension-type headache and dizziness.
The Behavior Pain Assessment Tool can assess pain in critically ill adults and in patients who cannot self-report pain.
Interventions may need to educate practitioners about how to handle difficult conversations with patients about opioids.
Pain management programs rooted in the biopsychosocial approach lead to reduced pain.
A significant number of patients reported that guided imagery intervention was beneficial for relieving pain, anxiety, and insomnia.
Results of brain imaging studies demonstrate that "hypnosis influences all of the cortical areas and neurophysiological processes that underlie pain and emotions."
Migraine was more significantly associated with muscle soreness or pain than anxiety disorders in patients with MDD.
Patients in the visual arm of the study wore flashing LED goggles delivering visual stimulation in the alpha-band range.
Evidence indicates that distraction can provide pain relief, highlighting the influence cognitive processes have on pain perception.
The major issues of drug development are that pre-clinical animal efficacy studies do not accurately predict human efficacy, and clinical trials often inaccurately fail to show drug efficacy.
Research on monogenic disorders has made vital contributions to all aspects of medical care, including our understanding of pain pathophysiology.
The recovery time varies depending on which class of medication the patient is overusing.
Connectivity in the right midfrontal gyrus may help predict placebo response. This finding has widespread implications in drug development.
The crystal structure may provide inspiration for designing drugs that refine efficacy and avoid adverse events.
The transfer of hyperalgesia is mediated by olfactory cues in mice, shedding light on the role of social and environmental cues in pain pathogenesis.
Patients with chronic pain often report feeling isolated and misunderstood, or that others believe they are exaggerating their pain or somehow using it to their benefit.
Even when knowing they were taking a placebo, patients still obtained relief from pain.
Dr Twillman, Executive Director for the American Academy of Pain Management, emphasizes the fact that CDC guidelines on opioids are expert- and not evidence-based.
Treating acute pain before it develops into chronic pain may be the key to preventing chronic pain from arising in the first place.
The DEA's plan to list kratom as a Schedule I controlled substance would make researching the possible opioid substitute much more difficult.
The strongest predictor of depression in patients with chronic stable angina was an episode of depression within the past 10 years.
Individuals with a history of abuse experience higher levels of pain, anxiety, and depression.
Researchers discovered novel opioid analgesics, displaying reduced respiratory depression.
Genetic factors and the environment patients share with their partner or spouse may determine their risk of developing chronic pain and help explain the association between chronic pain and depression.
An estimated 20-60% of patients with irritable bowel syndrome (IBS) have comorbid anxiety and/or depression.
Dr Darnall suggests that psychosocial factors are some of the most powerful determinants of pain outcomes.
The findings could have important clinical implications in the treatment of patients with arthritis.
Adolescents who experience chronic pain have higher prevalence of anxiety and depressive symptoms in adulthood.
Optogenetic tools enable light-based modulation of genetically defined neurons and temporally precise stimulation of neural circuit activity.
The Need For a Better Screening Tool